Differential pharmacotherapy for subgroups of fibromyalgia patients with specific consideration of 5-HT3 receptor antagonists

Author： Seidel Matthias F   Müüller Wolfgang  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.12, Iss.9, 2011-06, pp. : 1381-1391

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

5-HT3 receptor antagonists

By Higgins G.A.   Kilpatrick G.J.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 12, 1999-12 ,pp. : 2183-2188

Informa Healthcare

Access to resources Recommend Favorite

Advances in use of the 5-HT3 receptor antagonists

By Walton S.M.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 2, 2000-01 ,pp. : 207-223

Informa Healthcare

Access to resources Recommend Favorite

Are All 5-HT3 Receptor Antagonists the Same?

By McNulty Robert  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 5, Iss. 1, 2007-01 ,pp. : 35-43

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Clinical Pharmacology of Serotonin Receptor Type 3 (5-HT3) Antagonists

By  

Current Medicinal Chemistry - Central Nervous System Agents, Vol. 1, Iss. 2, 2001-08 ,pp. : 171-199

Bentham Science Publishers

Access to resources Recommend Favorite

The Effect of 5-HT 3 Receptor Antagonists on the Writhing Response in Mice

By Moser P.C.  

General Pharmacology, Vol. 26, Iss. 6, 1995-10 ,pp. : 1301-1306

Elsevier

Access to resources Recommend Favorite